Top 3 Canadian Biotech Stocks (Updated April 2022)

1. Hemostemix (TSXV:HEM)

Market cap: C$20.8 million; year-to-date gain: 128.13 percent

Hemostemix is a clinical-stage autologous stem cell therapy company. Founded in 2003, the firm develops, manufactures and commercializes blood-derived cell therapies from the patient’s own blood.

Hemostemix’s lead product, ACP-01, is designed for the treatment of critical limb ischemia, peripheral artery disease, angina, ischemic cardiomyopathy and dilated cardiomyopathy. Shares of the the top Canadian biotech stock hit a 2022 high point on April 19, clocking in at the C$0.34 level.

2. Fennec Pharmaceuticals (TSX:FRX)

Market cap: C$190.55 million; year-to-date gain: 42.86 percent

Late-stage biopharmaceutical company Fennec Pharmaceuticals is developing cancer drugs. Its lead candidate is PEDMARK, a treatment for pediatric cancer patients experiencing ototoxicity — hearing loss — as a result of platinum-based chemotherapy in pediatric patients.

The drug received breakthrough therapy and fast-track designation from the US Food and Drug Association (FDA) in March 2018. The European Medicines Agency is currently evaluating the marketing authorization application for the sodium thiosulfate-based treatment under the tradename PEDMARQSI. In late March, the company resubmitted its new drug application to the FDA for PEDMARK.

Company shares reached a year-to-date high of C$8 on April 14.

3. Antibe Therapeutics (TSX:ATE)

Market cap: C$40.98 million; year-to-date gain: 16.67 percent

Antibe Therapeutics is a clinical-stage biotech firm leveraging its proprietary hydrogen sulfide platform to develop safer pain and inflammation-reducing drugs. The company’s pipeline includes drug candidates that don’t bring about the gastrointestinal ulcers and bleeding associated with non-steroidal anti-inflammatory drugs (NSAIDs).

Antibe’s drug candidates under development include otenaproxesul, a safer alternative to opioids and NSAIDs for post-operative pain, and ATB-352 for a specialized pain indication. The company also plans to target inflammatory bowel disease with safer, more effective therapies. Shares marked a high of C$0.80 on March 28.